beta-alanine has been researched along with warfarin in 411 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 410 (99.76) | 24.3611 |
| 2020's | 1 (0.24) | 2.80 |
| Authors | Studies |
|---|---|
| Díaz-Cremades, JM; Fernández-Fuertes, F; Ruano, JA | 1 |
| Jamil-Copley, S; Kanagaratnam, P | 1 |
| Broukhim, M; Halperin, JL | 1 |
| Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP | 1 |
| Michota, F | 1 |
| Oliver, M | 1 |
| Aikens, TH; Brugada, J; Chernick, M; Connolly, SJ; Ezekowitz, MD; Flaker, G; Kamensky, G; Nagarakanti, R; Oldgren, J; Parekh, A; Reilly, PA; Yang, S; Yusuf, S | 1 |
| DeDea, L | 1 |
| Connolly, SJ | 1 |
| Kirsch, B | 1 |
| Connolly, SJ; Ezekowitz, MD; Hori, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Uchiyama, S | 2 |
| Beasley, BN; Temple, R; Unger, EF | 1 |
| Edwards, DB; Silverberg, J | 1 |
| Berg, AM | 1 |
| Cannon, CP; Stecker, EC | 1 |
| Fisher, WD | 1 |
| Alings, M; Connolly, SJ; Diener, HC; Eikelboom, JW; Ezekowitz, M; Franzosi, MG; Healey, JS; Hohnloser, SH; Huber, K; Kaatz, S; Oldgren, J; Reilly, P; Varrone, J; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Gage, BF; Shah, SV | 1 |
| Arnaout, S; Musallam, KM; Rabah, A; Sawaya, FJ; Sawaya, J | 1 |
| Batjer, HH; Bendok, BR; Bernstein, R; Rahme, RJ | 1 |
| Lee, TH | 1 |
| del Zoppo, GJ; Eliasziw, M | 1 |
| Ganjehei, L; Massumi, A; Rasekh, A; Razavi, M | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Mega, JL | 1 |
| Averkov, OV | 1 |
| Di Pasquale, G; Riva, L | 1 |
| Hunchuck, JE; Lake, JD | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Palareti, G; Pengo, V; Poli, D; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 3 |
| Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C | 1 |
| Bartholomew, JR; Wartak, SA | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Jolobe, OM | 1 |
| Yates, SW | 1 |
| Alings, M; Connolly, SJ; Darius, H; Diener, HC; Eikelboom, J; Ezekowitz, MD; Kamensky, G; Oldgren, J; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Beyth, RJ; Landefeld, CS | 1 |
| Al-Khatib, SM; Alexander, JH; Granger, CB; Lopes, RD; Mahaffey, KW; Patel, MR | 1 |
| Panchenko, EP | 1 |
| Smith, V | 1 |
| Diener, HC; Hohnloser, SH; Lip, GY; Weber, R | 1 |
| Deloughery, TG; Liem, TK | 2 |
| Büller, HR; Combe, S | 1 |
| Asakura, H | 1 |
| Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Brueckmann, M; Connolly, SJ; Eikelboom, J; Ezekowitz, M; Hohnloser, SH; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Freuler, M; Pezzotti, W | 1 |
| Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
| Diener, HC; Eikelboom, J; Granger, CB; Hacke, W | 1 |
| Govindarajan, R; Salgado, E | 1 |
| Parra, D; Reynolds, S; Rosenstein, RS | 1 |
| Reiffel, JA | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Knight, BP | 1 |
| Burkhardt, JD; Chalhoub, F; Coffey, J; D'Avila, A; Di Biase, L; Lakkireddy, D; Mansour, MC; Mohanty, P; Monir, G; Natale, A; Pimentel, R; Reddy, VY; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Shaik, N; Swarup, V; Vanga, SR | 1 |
| Easton, JD; Johnston, SC; Kamel, H; Kim, AS | 1 |
| Abraham, ME; Marcy, TR | 1 |
| Alpert, JS | 1 |
| Brueckmann, M; Connolly, S; Ezekowitz, M; Flaker, G; Hohnloser, SH; Noack, H; Reilly, P; Wallentin, L; Yusuf, S | 1 |
| Adcock, AK; Aguilar, MI; Demaerschalk, BM; Hoffman-Snyder, CR; Lee-Iannotti, JK; Wellik, KE; Wingerchuk, DM | 1 |
| Abdelhafiz, AH; Ali, A; Bailey, C | 1 |
| Pazmiño, PA | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| DiNicolantonio, JJ | 1 |
| Bryer, A | 1 |
| Baumgarten, P; Bohmann, F; Foerch, C; Lindhoff-Last, E; Mittelbronn, M; Pfeilschifter, J; Pfeilschifter, W; Steinmetz, H | 1 |
| Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
| Connolly, SJ; Diener, HC; Ezekowitz, MD; Hart, RG; Reilly, PA; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Baker, RI; Harper, P; McLintock, C | 1 |
| Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Spinewine, A; Sternotte, A | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
| Bianco, RW; Lahti, MT; Medina, EM; Schomburg, JL | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Schulman, S | 4 |
| Aguilar, MI; Freeman, WD; Kuo, R | 1 |
| Vanerio, G; Vidal, A | 1 |
| Firriolo, FJ; Hupp, WS | 1 |
| Das, P; Jha, SK; Kabra, R; Koshy, SK; Shaheen, MH | 1 |
| Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
| Freeman, MK; Hughes, PJ | 1 |
| Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Heidbuchle, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Garcia, DA; Granger, CB | 1 |
| Bhatt, DL; Kar, S | 1 |
| Ataullakhanov, FI; Panteleev, MA; Sinauridze, EI | 1 |
| Davidson, T; Husberg, M; Janzon, M; Levin, LÅ; Oldgren, J | 1 |
| Callahan, S; Goldsberry, A; Kim, G; Yoo, S | 1 |
| Ansell, J; Mantha, S | 1 |
| Cheng, G; Tsui, KK; Wong, RS; You, JH | 1 |
| Radecki, RP | 1 |
| Finsterer, J; Stöllberger, C | 2 |
| Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
| Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Reed, SD | 1 |
| Bilen, O; Teruya, J | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Huang, C; Shin, J; Siu, M; Vu, L; Wong, S | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Zhang, S | 1 |
| Al-Sallami, HS; Duffull, SB; Faed, JM; Wright, DF; Zufferey, PJ | 1 |
| Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
| Johns, G; Kauffman, C; Kusumoto, F; Prussak, K; Snipelisky, D; Venkatachalam, K | 1 |
| Griffiths, M; Scully, C | 1 |
| Taylor, J | 1 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
| Nguyen, T; Wong, E | 1 |
| Alonso-Coello, P; Guyatt, G; Zhou, Q | 1 |
| Ahmad, Y; Lip, GY | 2 |
| Alexander, GC; Kirley, K; Kornfield, R; Qato, DM; Stafford, RS | 1 |
| Álvarez-Sabin, J; Becerra, V; González-Juanatey, JR; González-Rojas, N; Lobos, JM; Martínez-Rubio, A; Oyagüez, I; Reverter, JC | 1 |
| Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
| Cheema, AA; Jones, P; Konduru, SV; Li, Y; Ramza, B; Wimmer, AP | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Gonzalez, MD; Naccarelli, GV | 1 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| McBane, RD; Tafur, A; Wysokinski, WE | 1 |
| Merli, GJ | 1 |
| Aalbers, J | 1 |
| Chang, AM; Ho, JC; Lam, YY; Lee, VW; Yan, BP; Yu, CM | 2 |
| Valle Bernad, R | 1 |
| Blanco-Molina, A | 1 |
| Hirayama, H; Inden, Y; Kamiya, H; Murohara, T; Nanasato, M; Nin, T; Sairaku, A; Tatematsu, Y; Yoshida, Y | 1 |
| Okada, Y; Yasaka, M | 2 |
| Wooten, JM | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Gross, PL; Weitz, JI | 1 |
| Bogun, F; Carrigan, T; Chugh, A; Crawford, T; Ghanbari, H; Good, E; Jongnarangsin, K; Kennedy, R; Kim, JS; Latchamsetty, R; Morady, F; Oral, H; Pelosi, F; Saint-Phard, W; She, F; Sinno, M; Suwanagool, A; Yokokawa, M | 1 |
| Connolly, SJ; Coppens, M; Dale, B; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Paikin, JS; Weitz, JI; Whitlock, RP; Young, E | 1 |
| Kanorsky, SG; Shevelev, VI | 1 |
| Deitelzweig, SB | 1 |
| Greenspon, AJ | 1 |
| Brem, E; Foran, M; Koyfman, A | 1 |
| Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL | 1 |
| Dyrkorn, R; Roland, PD | 1 |
| Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S | 1 |
| Connors, JM | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| Devlin, HL; Hosman, AE; Shovlin, CL | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Dolgin, E | 1 |
| Reichman, ME; Southworth, MR; Unger, EF | 1 |
| Albaladejo, P; David, JS; Piriou, V | 1 |
| Hjemdahl, P; Johnsson, H; Wallén, NH | 1 |
| Camarero, MO; Castaño, MP; Milla, SL; Piñero-Saavedra, M | 1 |
| Berger, R; Chase, M; Ganetsky, M; Salhanick, SD | 1 |
| Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP | 1 |
| Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
| Abi-Saleh, B; Alam, S; Baranowski, B; Bassiouny, M; Borek, PP; Callahan, T; Chung, M; Diab, M; Dresing, T; Hussein, A; Kanj, M; Khoury, M; Lindsay, BD; Martin, DO; Niebauer, M; Rickard, J; Saliba, W; Sengupta, J; Sey, A; Shao, M; Tchou, PJ; Varma, N; Wazni, O | 2 |
| Doppalapudi, H; Gunter, A; Kay, GN; Maddox, W; McElderry, HT; Osorio, J; Plumb, VJ; Yamada, T | 1 |
| Attia, JR; Pearce, R | 1 |
| Eikelboom, JW; Hankey, GJ | 1 |
| Jeffery, SM; Ogbonna, KC | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Limdi, NA; Thigpen, JL | 1 |
| Chevalier, J; de Pouvourville, G; Giroud, M | 1 |
| Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Bradley-Kennedy, C; Kansal, AR; Monz, BU; Peng, S; Sorensen, SV | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Asmussen, MB; Hesselbjerg, LJ; Pedersen, HS; Petersen, KD | 1 |
| Ellis, CR; Kaiser, DW; Nagarakanti, R; Streur, MM; Whalen, SP | 1 |
| Yasaka, M | 1 |
| Avila, C; Gullett, D; Johnson, ES; Kokaram, CR; Parra, MW; Wichner, ZA; Zucker, L | 1 |
| Kalus, JS | 1 |
| Avezum, A; Connolly, SJ; Douketis, J; Eikelboom, J; Ezekowitz, M; Healey, JS; Heidbuchel, H; Oldgren, J; Reilly, P; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Atay, JK; Barnes, GD; Coatney, J; Ehle, M; Fanikos, J; Froehlich, JB; Goldhaber, SZ; Piazza, G | 1 |
| Pelargonio, G; Perna, F | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Connolly, SJ; Korhonen, M; Monz, BU; Noack, H; Pooley, J | 1 |
| Bett, N; Hamilton-Craig, C; Luis, C; Luis, SA; Poon, K; Shukla, A | 1 |
| Micieli, A; Singh, SM; Wijeysundera, HC | 1 |
| Heidenreich, PA | 1 |
| Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
| Bauer, KA | 1 |
| Klein, HH | 1 |
| Amnueypol, M; Calkins, H; Haines, DE; Marchlinski, FE; Mead-Salley, M; Nademanee, K; Saklani, P; Salazar, M; Skanes, AC; Yarmohammadi, H; Zado, E | 1 |
| Bovio, JA; Franck, AJ | 1 |
| Hegerfeldt, Y | 1 |
| Edwards, JL | 1 |
| Connolly, SJ; Eikelboom, JW; Hart, RG; Oldgren, J; Reilly, P; Wallentin, L; Yang, S; Yusuf, S | 1 |
| Pollack, CV | 1 |
| Gong, IY; Kim, RB | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Diener, HC | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Brueckmann, M; Connolly, SJ; Ezekowitz, MD; Ferreira, J; Fraessdorf, M; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Bhimani, AA; Hong, M | 1 |
| Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Bamimore, A; Mounsey, JP | 1 |
| Djalali, S | 1 |
| Albenque, JP; Bouzeman, A; Boveda, S; Casteigt, B; Combes, N; Combes, S; Marijon, E; Narayanan, K; Providência, R | 1 |
| Doppalapudi, H; Gunter, A; Jennings, JM; Kay, GN; McElderry, HT; Osorio, J; Plumb, VJ; Robichaux, R; Yamada, T | 1 |
| Daoud, EG; Kahwash, R | 1 |
| Fauchier, L; Gruel, Y; May, MA | 1 |
| Dalen, JE | 1 |
| DeRemer, CE; Elewa, HF; Gujral, J; Joshua, TV; Keller, K | 1 |
| Bell, S; Dawes, M; Nand, J | 1 |
| Fanikos, J | 1 |
| Dinkel, J; Foerch, C; Gupta, R; Hayakawa, K; Karatas, H; Lauer, A; Leung, W; Lo, EH; Schlunk, F; Steinmetz, H; Won, SY | 1 |
| Davis, C; Lee, M; Robertson, C; Shivakumar, S | 1 |
| Alvrtsyan, H; Francis, K; Matchar, D; Miyasato, G; Rao, Y; Sanchez, H; Sander, S; Siu, K; Walker, D; Yu, C; Zalesak, M | 1 |
| Avorn, J | 1 |
| Hamasaki, S; Ichiki, H; Iriki, Y; Ishida, S; Maenosono, R; Miyata, M; Namino, F; Ninomiya, Y; Oketani, N; Okui, H; Tei, C | 1 |
| Ansell, J; Shameem, R | 1 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T | 1 |
| Eriksson, BI; Quinlan, DJ | 1 |
| Cohen, AA; Rider, T | 1 |
| Lip, GY; Van Gelder, IC; Van Veldhuisen, DJ | 1 |
| Doraiswamy, VA; Gesheff, MG; Gurbel, PA; Slepian, MJ; Tantry, US | 1 |
| Rosenfeld, JV; Schaerf, NB; Thomas, PA | 1 |
| Hylek, EM | 1 |
| Blatchford, J; Brueckmann, M; Connolly, SJ; Devenny, K; Eikelboom, JW; Friedman, J; Granger, CB; Guiver, K; Harper, R; Kappetein, AP; Khder, Y; Lobmeyer, MT; Maas, H; Mack, MJ; Simoons, ML; Van de Werf, F; Voigt, JU | 1 |
| Crystal, E; Danon, A; Healey, JS; Kansal, N; Lashevsky, I; Morillo, CA; Newman, D; Schulman, S; Shurrab, M | 1 |
| Brodsky, SV; Hebert, L; Nadasdy, G; Nadasdy, T; Qamri, Z; Rovin, B; Ryan, M; Satoskar, A; Ware, K; Wu, H | 1 |
| Brueckmann, M; Connolly, S; Eikelboom, J; Ezekowitz, M; Le Heuzey, JY; Marijon, E; Pogue, J; Themeles, E; Wallentin, L; Yang, S; Yusuf, S | 2 |
| Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
| Roberts, A | 1 |
| Azuma, S; Lum, CJ | 1 |
| Holmes, D | 1 |
| Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 1 |
| Artang, R; Nielsen, JD; Rome, E; Vidaillet, HJ | 1 |
| Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S | 2 |
| Paré, G; Ross, S | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Chandler, WL | 1 |
| Bin Abdulhak, AA; Khan, AR; Tleyjeh, IM; Wimmer, AP | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Cove, CL; Hylek, EM | 1 |
| Curnew, G; Holbrook, A; Hong, C; Kim, S; Pullenayegum, E; Schulman, S | 1 |
| Avorn, J; Brennan, TA; Canestaro, WJ; Choudhry, NK; Ito, K; Matlin, OS; Patrick, AR; Shrank, WH | 1 |
| Celik, S; Sipahi, I; Tozun, N | 1 |
| Abe, K; Deguchi, K; Ikeda, Y; Kono, S; Kurata, T; Omote, Y; Yamashita, T; Yunoki, T | 1 |
| Manning, JA | 1 |
| Kitazono, T | 1 |
| Laffan, M; Shapiro, S | 1 |
| Andersson, U; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Hijazi, Z; Hohnloser, SH; Oldgren, J; Reilly, PA; Siegbahn, A; Wallentin, L; Yusuf, S | 2 |
| Clemens, A; Connolly, SJ; Ferreira, J; Lip, GY; Noack, H; Yusuf, S | 1 |
| Albenque, JP; Boveda, S; Marijon, E; Providência, R | 1 |
| Kolias, TJ | 1 |
| Bounameaux, H; Verhamme, P | 1 |
| Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S | 1 |
| Pai, RG; Tafreshi, J; Zough, F | 1 |
| Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 2 |
| Christensen, TD; Larsen, TB | 1 |
| Brueckmann, M; Eikelboom, JW; van de Werf, F | 2 |
| Battista, M; Guglielmetti, G; Stratta, P | 1 |
| Sharma, S; Singh, S | 1 |
| Deakin, A; Speirs, A | 1 |
| Begg, EJ; Chin, PK; Wright, DF | 1 |
| Biocina, B; Gasparovic, H; Petricevic, M | 1 |
| Bajorek, B; Wang, Y | 1 |
| Stewart, RA | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Gorst-Rasmussen, A; Larsen, TB; Lip, GY; Rasmussen, LH; Rosenzweig, M; Skjøth, F | 1 |
| Foerch, C; Lauer, A; Leung, W; Lo, EH; Lok, J; Schaefer, JH; Van Cott, EM; van Leyen, K; van Ryn, J; Whalen, M; Wu, L | 1 |
| Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
| Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V | 1 |
| Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C | 1 |
| Cordova, EG; del Aguila, D; Salazar, CA | 1 |
| Thachil, J | 1 |
| Hagen, G; Klemp, M; Wisløff, T | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Ibrahim, S; Jespersen, J; Poller, L | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Brannath, W; Schmidt, S | 1 |
| Brieger, D | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| Cohen, AT; Granziera, S | 1 |
| Birnie, DH; Essebag, V; Healey, JS | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Breik, O; Cheng, A; Goss, A; Sambrook, P | 1 |
| Fernández de Velasco Pérez, D | 1 |
| Hess, T; Konturek, P | 1 |
| Baker, WL; Chamberlin, KW | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Alonso, A; Bengtson, LG; Chen, LY; Lakshminarayan, K; Lutsey, PL; MacLehose, RF | 1 |
| Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A | 1 |
| Askonen, K; Halinen, M; Huikuri, H; Koistinen, J; Parikka, H; Puurunen, M; Raatikainen, P; Virtanen, V | 1 |
| Brodsky, SV; Hebert, LA; Ivanov, I; Muni, N; Nadasdy, G; Nadasdy, T; Rovin, BH; Satoskar, AA; Vance, JC; Ware, KM | 1 |
| AbuDagga, A; Fu, AC; Kwong, WJ; Stephenson, JJ; Tan, H; Weintraub, WS | 1 |
| Cohen, MR; Mattison, DR; Moore, TJ | 1 |
| McCormick, NJ; Meechan, JG; Moore, UJ; Norouzi, M | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Chrischilles, E; Cram, P; Jones, M; Mazur, A; Vaughan Sarrazin, MS | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Punjabi, PP; Sarvananthan, S | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Beurtheret, S; Seitz, J | 1 |
| Brueckmann, M; Clemens, A; Konstantinides, S; Lip, GY; Noack, H; Strack, A | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Carroll, VS; Frei, J | 1 |
| Gorst-Rasmussen, A; Lane, DA; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Hifumi, T; Kiriu, N; Takada, H | 1 |
| Bennell, MC; Krahn, M; Micieli, A; Pham, B; Singh, SM; Wijeysundera, HC | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Connolly, SJ; Wallentin, L; Yusuf, S | 1 |
| Bollmann, A; Breithardt, OA; Darma, A; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Barnes, GD; Eagle, KA; Froehlich, JB | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Ammollo, CT; Colucci, M; Semeraro, N; Testa, S; Visino, F; Zaccaria, F | 1 |
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Kovács, T | 1 |
| Shah, R | 1 |
| Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F | 1 |
| de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Goulding, MR; Graham, DJ; Houstoun, M; Kelman, JA; Levenson, M; MaCurdy, TE; Mott, K; Reichman, ME; Sheu, TC; Southworth, MR; Wernecke, M; Worrall, C; Zhang, R | 1 |
| Redberg, RF | 1 |
| Baik, SH; Hernandez, I; Piñera, A; Zhang, Y | 1 |
| Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 1 |
| Eikelboom, JW; Hart, RG | 1 |
| Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Lau, CP; Lau, KK; Leung, GK; Lip, GY; Siu, CW; Tse, HF; Yeung, CY | 1 |
| Chin, PK; Florkowski, CM; Wright, DF | 1 |
| Carney, EF | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Belikov, LN; Savchuk, OF; Sukovatykh, BS; Sukovatykh, MB | 1 |
| Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
| Rockey, DC | 1 |
| Einecke, D | 1 |
| Cantürk, E; Güler, E; Karaca, O; Kızılırmak, F; Omaygenç, O | 1 |
| Hasler, S | 1 |
| Feng, X; Huan, Y; Lv, Y | 1 |
| Chan, PH; Hai, JJ; Siu, CW | 1 |
| Crighton, A; Gibson, J; Scott, A | 1 |
| Bultas, J | 1 |
| Beauchesne, M; Blais, L; Brais, C; Farand, P; Larochelle, J; Letemplier, G; Perreault, S; Tousignant, A; Turgeon, M | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Oberhofer, E | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Bosch, J; Eikelboom, JW | 1 |
| Mracsko, E; Na, SY; van Ryn, J; Veltkamp, R | 1 |
| Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S | 1 |
| Alexander, GC; Chang, HY; Singh, S; Tang, W; Zhou, M | 1 |
| Rose, A; Vaughan Sarrazin, MS | 1 |
| Gehrie, E; Tormey, C | 1 |
| Phillips, R | 1 |
| Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N | 1 |
| Lythgoe, M | 1 |
| Lewis, LS | 1 |
| Miyares, MA | 1 |
| Brewster, LM; Horjus, DL; van Montfrans, GA | 1 |
| Azoulay, L; Klil-Drori, A | 1 |
| Kreuzer, J; Zint, K | 1 |
| Kim, CO; Liu, S; Lucyk, SN | 1 |
| Damkier, P; Hansen, MR; Henriksen, DP | 1 |
| Hernandez, I; Zhang, Y | 1 |
| Koretz, RL | 1 |
| Lavine, JB | 1 |
| Potpara, TS | 1 |
| McBane, RD; Schaefer, JK; Wysokinski, WE | 1 |
| Torjesen, I | 1 |
| Alonso, A; Bengtson, LGS; Chen, LY; Lutsey, PL; MacLehose, RF | 1 |
| Ummarino, D | 1 |
| Sugiyama, T | 1 |
| Chan, EW; Lau, WCY; Wong, ICK | 1 |
| Calkins, H; Nordaby, M | 1 |
| Seligman, SJ | 1 |
| Larsen, JM; Løfgren, B; Pareek, M | 1 |
| Dobrev, D; Fender, AC | 1 |
| Aggarwal, R; Aghoram, R; Kar, SS; Kumar, SM; Rajasulochana, SR | 1 |
125 review(s) available for beta-alanine and warfarin
| Article | Year |
|---|---|
Stroke in atrial fibrillation--hope on the horizon?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Heart Atria; Humans; Prostheses and Implants; Stroke; Warfarin | 2010 |
Stroke prevention in the high-risk atrial fibrillation patient: Medical management.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Health Status Indicators; Humans; Risk Assessment; Stroke; Vitamin K; Warfarin | 2011 |
Intracerebral hemorrhage: Pick your poison.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chronic Disease; Dabigatran; Humans; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Venous Thromboembolism; Warfarin | 2010 |
Atrial fibrillation in 2010: advances in treatment and management.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
[Dabigatran, a new oral anticoagulant].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2011 |
New options for stroke prevention in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2010 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin | 2011 |
Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Stroke; Warfarin | 2011 |
Stroke prevention in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Catheterization; Cardiac Surgical Procedures; Dabigatran; Humans; Preventive Health Services; Stroke; Treatment Outcome; Warfarin | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
[Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Echocardiography, Three-Dimensional; Electric Countershock; Humans; International Normalized Ratio; Premedication; Randomized Controlled Trials as Topic; Risk Adjustment; Thromboembolism; Time Factors; Warfarin | 2011 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Evidence-Based Medicine; Hemorrhage; Humans; Italy; Patient Selection; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2011 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Stroke; Warfarin | 2012 |
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biopharmaceutics; Blood Coagulation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Approval; Drug Dosage Calculations; Drug Monitoring; Humans; Risk Assessment; Therapeutic Equivalency; Thrombin; Thromboembolism; Warfarin | 2011 |
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Humans; Pyrazoles; Pyridones; Risk Factors; Stroke; Warfarin | 2011 |
Promise of factor Xa inhibition in atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Randomized Controlled Trials as Topic; Risk Factors; Stroke; United States; Warfarin | 2012 |
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemodynamics; Hemorrhage; Humans; Risk Factors; Stroke; Therapeutic Equivalency; Treatment Outcome; Ventricular Dysfunction, Left; Warfarin | 2011 |
Stroke prevention in atrial fibrillation: do we still need warfarin?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Decision Making; Factor Xa Inhibitors; Humans; Risk Factors; Stroke; Thrombin; Vitamin K; Warfarin | 2012 |
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Venous Thromboembolism; Warfarin | 2011 |
[Interpretation of hemostatic and fibrinolytic markers].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Platelets; Dabigatran; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hemostasis; Humans; Partial Thromboplastin Time; Plasminogen Activators; Prothrombin Time; Thrombomodulin; Warfarin | 2011 |
Using anticoagulants to steer clear of clots.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Heparin; Humans; Thrombosis; Warfarin | 2012 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Warfarin versus dabigatran: comparing the old with the new.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Warfarin | 2012 |
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Male; Stroke; Warfarin | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; International Normalized Ratio; Liver; Myocardial Infarction; Warfarin | 2012 |
Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Stroke; Warfarin | 2012 |
[Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Monitoring, Physiologic; Platelet Aggregation; Stroke; Thromboembolism; Warfarin | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Treatment of venous thromboembolism with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
Dabigatran and left atrial appendage thrombus.
Topics: Antithrombins; Atrial Appendage; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Diseases; Humans; Middle Aged; Thrombosis; Warfarin | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
Anticoagulant therapy: basic principles, classic approaches and recent developments.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Hirudins; Humans; Platelet Aggregation Inhibitors; Thrombin; Thromboembolism; Thrombophilia; Venous Thrombosis; Vitamin K; Warfarin | 2012 |
The management of antithrombotic medication in skin surgery.
Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Complications of anticoagulation.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Contamination; Drug Monitoring; Food-Drug Interactions; Hemorrhage; Heparin; Humans; Hypersensitivity; Injections, Subcutaneous; Necrosis; Osteoporosis; Skin Diseases; Subcutaneous Tissue; Thrombocytopenia; Warfarin | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Monitoring, Ambulatory; Self Care; Stroke; Thromboembolism; Vitamin K; Warfarin | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
Comparing new anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New oral anticoagulants: which one should my patient use?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hematology; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Warfarin | 2012 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
New anticoagulants in atrial fibrillation management.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coumarins; Dabigatran; Female; Hematology; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Sex Factors; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Reversal of oral anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Hemorrhage; Humans; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
[Direct oral thrombin inhibitor, "dabigatran"].
Topics: Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Warfarin | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Managing bleeding in anticoagulated patients in the emergency care setting.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Hemorrhage; Hemostasis; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Topics: Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Postoperative Hemorrhage; Pyridines; Surgery, Oral; Tooth Extraction; Warfarin | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Warfarin | 2013 |
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Perioperative Care; Stroke; Warfarin | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.
Topics: Amidines; Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticlopidine; Warfarin | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessment; Stroke; Venous Thromboembolism; Warfarin | 2013 |
A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Pharmaceutical; Gastrointestinal Hemorrhage; Humans; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Warfarin | 2014 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Topics: Amidines; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Drug Administration Schedule; Embolism; Female; Humans; Male; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Stroke; Vitamin K; Warfarin | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Management of anticoagulation around pacemaker and defibrillator surgery.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Defibrillators, Implantable; Humans; Intracranial Embolism; Male; Pacemaker, Artificial; Warfarin | 2014 |
Protocol in managing oral surgical patients taking dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Female; Humans; Male; Oral Surgical Procedures; Tooth Extraction; Warfarin; Withholding Treatment | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2014 |
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
[Update on current care guideline: atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Incidence; Morpholines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Oral anticoagulants: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Kidney Function Tests; Morpholines; Perioperative Period; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin | 2016 |
27 trial(s) available for beta-alanine and warfarin
| Article | Year |
|---|---|
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Echocardiography, Transesophageal; Electric Countershock; Electric Stimulation Therapy; Hemorrhage; Humans; Incidence; Retrospective Studies; Stroke; Warfarin | 2011 |
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Japan; Male; Stroke; Warfarin | 2011 |
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Factors; Time Factors; Warfarin | 2011 |
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cause of Death; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Risk Assessment; Risk Factors; Stroke; Thromboembolism; Warfarin | 2011 |
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Heart Arrest; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Risk Factors; Single-Blind Method; Warfarin | 2012 |
[Expectation to and problems of thrombin inhibitor].
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2011 |
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Radiography; Risk Factors; Warfarin | 2012 |
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Brain Ischemia; Cardiac Pacing, Artificial; Cataract Extraction; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Risk Factors; Stroke; Thromboembolism; Warfarin | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Humans; Life Expectancy; Quality-Adjusted Life Years; Stroke; Sweden; Warfarin | 2013 |
Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Middle Aged; Perioperative Care; Thromboembolism; Warfarin | 2012 |
A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Perioperative Care; Premedication; Thrombosis; Treatment Outcome; Warfarin | 2013 |
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Myocardial Infarction; Thrombin; Warfarin | 2013 |
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Intention to Treat Analysis; International Normalized Ratio; Male; Middle Aged; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult | 2013 |
Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Prospective Studies; Quality of Life; Warfarin | 2013 |
Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Catheter Ablation; Comorbidity; Dabigatran; Decision Making; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Postoperative Complications; Premedication; Risk Factors; Thromboembolism; Treatment Outcome; United States; Warfarin | 2013 |
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2013 |
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Risk Factors; Stroke; Warfarin | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Drug Substitution; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Warfarin | 2014 |
Dabigatran versus warfarin in patients with mechanical heart valves.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Hemorrhage; Humans; Male; Middle Aged; Stroke; Thromboembolism; Warfarin | 2013 |
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cause of Death; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Predictive Value of Tests; Risk Factors; Warfarin | 2013 |
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Choice Behavior; Dabigatran; Decision Support Techniques; Female; Humans; Male; Middle Aged; Warfarin | 2013 |
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Embolism; Female; Glomerular Filtration Rate; Humans; Internationality; Kidney; Male; Middle Aged; Models, Biological; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2014 |
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Risk Factors; Venous Thromboembolism; Warfarin; Young Adult | 2014 |
Warfarin or dabigatran for treatment of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Europe; Hemorrhage; Humans; Software; Thromboembolism; Warfarin | 2014 |
Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Dabigatran; Female; Hemoglobins; Humans; Incidence; Male; Middle Aged; Pacemaker, Artificial; Postoperative Hemorrhage; Prospective Studies; Warfarin | 2014 |
261 other study(ies) available for beta-alanine and warfarin
| Article | Year |
|---|---|
When a virtue becomes a problem. The new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Medication Adherence; Risk; Vitamin K; Warfarin | 2010 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; Risk Factors; Sensitivity and Specificity; Stroke; Warfarin | 2011 |
Warfarin or not.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism; Warfarin | 2010 |
The difference between Tdap and DTaP; dabigatran versus warfarin.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diphtheria-Tetanus-acellular Pertussis Vaccines; Humans; Product Surveillance, Postmarketing; Warfarin | 2011 |
Next generation anticoagulants may push warfarin to the wayside.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Evaluation; Humans; Medication Adherence; Stroke; Warfarin | 2011 |
New drug offers warfarin alternative for atrial fibrillation. An immediate switch is right for some people, but not necessary for all.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug and Narcotic Control; Drug Approval; Humans; United States; United States Food and Drug Administration; Warfarin | 2011 |
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Embolism; Hemorrhage; Humans; Stroke; Therapeutic Equivalency; United States; United States Food and Drug Administration; Warfarin | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Health Care Costs; Humans; Stroke; Warfarin | 2011 |
Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Fibrinolytic Agents; Health Care Costs; Humans; Stroke; Warfarin | 2011 |
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Decision Trees; Hemorrhage; Humans; Markov Chains; Risk Factors; Stroke; Warfarin | 2011 |
Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Thrombosis; Dabigatran; Humans; Male; Recurrence; Stroke; Ultrasonography; Warfarin | 2012 |
Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Patient Education as Topic; Warfarin | 2011 |
New options in anticoagulation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to Treat Analysis; Intracranial Hemorrhages; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
Dabigatran for stroke prevention in all patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Stroke; Warfarin | 2011 |
The use of dabigatran immediately after atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Tolerance; Female; Follow-Up Studies; Glomerular Filtration Rate; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Thrombin; Thromboembolism; Treatment Outcome; Warfarin | 2012 |
Dabigatran: will it change clinical practice?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Embolism; Humans; Stroke; United States; Warfarin | 2011 |
Lack of an antagonist to reverse the action of dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Female; Hemorrhage; Humans; Male; Stroke; Warfarin | 2011 |
Dabigatran (OCTOBER 2011).
Topics: Benzimidazoles; beta-Alanine; Embolism; Humans; Stroke; Warfarin | 2011 |
[New treatments for venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thrombosis; Warfarin | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Randomized Controlled Trials as Topic; Risk; Risk Factors; Stroke; Thrombin; Warfarin | 2012 |
Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2012 |
Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) tri
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2012 |
Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2012 |
Anticoagulation for atrial fibrillation ablation: what is the optimal strategy?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Registries; Warfarin | 2012 |
Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Feasibility Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Registries; Thromboembolism; Treatment Outcome; Warfarin | 2012 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Costs; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Markov Chains; Models, Statistical; Monte Carlo Method; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Electrocardiography; Embolism; Female; Follow-Up Studies; Heart Rate; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome; Warfarin | 2012 |
Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; International Normalized Ratio; Male; Middle Aged; Prospective Studies; Risk Factors; Stroke; Treatment Outcome; Warfarin | 2012 |
Dabigatran (OCTOBER 2011).
Topics: Benzimidazoles; beta-Alanine; Embolism; Humans; Stroke; Warfarin | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Drug Interactions; Fibrinolytic Agents; Mice; Mice, Inbred C57BL; Stroke; Tissue Plasminogen Activator; Warfarin | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
Avoiding adverse events with dabigatran by careful selection of eligible patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Hemorrhage; Humans; Patient Selection; Stroke; Warfarin | 2012 |
Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation, Preclinical; Female; Heart Valve Prosthesis; Hemorrhage; Male; Mitral Valve; Models, Animal; Sus scrofa; Thrombosis; Warfarin | 2012 |
Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; Warfarin | 2012 |
Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Narcotics; Oral Hemorrhage; Oral Surgical Procedures; Postoperative Hemorrhage; Rivaroxaban; Thiophenes; Warfarin | 2012 |
An anticoagulation option for nonvalvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Humans; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Stroke; Warfarin | 2012 |
Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
Topics: Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Prospective Studies; Stroke; Thromboembolism; Warfarin | 2012 |
Anticoagulation, novel agents, and procedures: can we pardon the interruption?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Thromboembolism; Warfarin | 2012 |
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Genotype; Humans; Stroke; Warfarin | 2012 |
Dabigatran: uncharted waters and potential harms.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pharmacovigilance; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Warfarin | 2012 |
Letter by Stollberger and Finsterer regarding article, "intracranial hemorrhage in patients with atrial fibrillation during anticoagulation with Warfarin or Dabigatran: the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; Warfarin | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
How country-specific should a country-specific cost-effectiveness analysis be?
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Warfarin | 2013 |
Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Eligibility Determination; Fees, Pharmaceutical; Female; Health Care Surveys; Hemorrhage; Humans; Male; Middle Aged; Patient Preference; Patient Selection; Practice Patterns, Physicians'; Surveys and Questionnaires; United States; Warfarin | 2013 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Survival Rate; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
Dabigatran: rational dose individualisation and monitoring guidance is needed.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; New Zealand; Warfarin | 2012 |
A comparison of bleeding complications post-ablation between warfarin and dabigatran.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Stroke; Treatment Outcome; Warfarin | 2012 |
New anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Evaluating and assessing dabigatran drug interactions.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Consultants; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Monitoring; Female; Humans; International Normalized Ratio; Middle Aged; Pharmaceutical Services; Pharmacists; Professional Role; Warfarin | 2012 |
National trends in oral anticoagulant use in the United States, 2007 to 2011.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Costs; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Guideline Adherence; Health Care Surveys; Health Expenditures; Humans; Medical Audit; Middle Aged; Off-Label Use; Practice Guidelines as Topic; Practice Patterns, Physicians'; Preventive Health Services; Thromboembolism; Time Factors; United States; Warfarin | 2012 |
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Embolism; Female; Humans; Male; Markov Chains; Spain; Stroke; Vitamin K; Warfarin | 2012 |
Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Humans; Stroke; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2011 |
Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Registries; Warfarin | 2012 |
Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Female; Heparin; Humans; Linear Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Risk Factors; Treatment Outcome; Warfarin | 2012 |
Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; United States; Warfarin | 2013 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin | 2012 |
The new oral anticoagulants: a challenge for hospital formularies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Formularies, Hospital as Topic; Humans; Morpholines; Pennsylvania; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Europe; Humans; Postoperative Complications; Practice Guidelines as Topic; United States; Vascular Surgical Procedures; Venous Thromboembolism; Warfarin | 2012 |
Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hong Kong; Humans; Male; Quality of Life; Retrospective Studies; Stroke; Warfarin | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Management of intracranial hemorrhage during anticoagulant therapy with warfarin or novel anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Humans; Intracranial Embolism; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Case-Control Studies; Catheter Ablation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Transesophageal; Electrocardiography; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Postoperative Care; Predictive Value of Tests; Preoperative Care; Reference Values; Risk Assessment; Severity of Illness Index; Thromboembolism; Treatment Outcome; Warfarin | 2013 |
[Safety and efficacy of various modalities of antiplatelet prophylaxis of ischemic stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clopidogrel; Dabigatran; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Stroke; Thromboembolism; Ticlopidine; Warfarin | 2012 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[New anticoagulants--should we have a little bit of cold water in the blood?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Extended treatment of venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin | 2013 |
Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Platelet Aggregation Inhibitors; Telangiectasia, Hereditary Hemorrhagic; Warfarin | 2013 |
Dabigatran "non-inferior" to warfarin, but only just.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Pulmonary Embolism; Treatment Outcome; Venous Thrombosis; Warfarin | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Antidotes edge closer to reversing effects of new blood thinners.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Humans; Pyrazoles; Pyridones; Recombinant Proteins; Vitamin K; Warfarin | 2013 |
Dabigatran and postmarketing reports of bleeding.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Warfarin | 2013 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Drug Utilization Review; Female; Health Expenditures; Hong Kong; Hospital Costs; Hospitals, Teaching; Humans; Male; Middle Aged; Preventive Health Services; Retrospective Studies; Stroke; Treatment Outcome; Warfarin | 2013 |
Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; Warfarin | 2013 |
Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; Warfarin | 2013 |
DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran: a case report.
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Eruptions; Eosinophilia; Exanthema; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Prospective Studies; Stroke; Warfarin | 2013 |
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Female; Humans; International Normalized Ratio; Male; Markov Chains; Myocardial Infarction; Quality-Adjusted Life Years; South Africa; Stroke; Warfarin | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confidence Intervals; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Intraoperative Care; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Perioperative Care; Postoperative Complications; Prospective Studies; Registries; Risk Assessment; Severity of Illness Index; Survival Rate; Thromboembolism; Thrombolytic Therapy; Treatment Outcome; Warfarin | 2013 |
Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Echocardiography, Transesophageal; Female; Humans; Male; Middle Aged; Postoperative Complications; Pulmonary Veins; Warfarin | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency; Research Design; Selection Bias; Stroke; Warfarin | 2013 |
Is there really misuse and abuse of dabigatran?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Research Design; Stroke; Warfarin | 2013 |
Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Computer Simulation; Dabigatran; Decision Support Techniques; Decision Trees; Female; France; Health Services Research; Humans; Incidence; Male; Models, Statistical; Multivariate Analysis; Outcome and Process Assessment, Health Care; Prevalence; Registries; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood-Brain Barrier; Cerebral Arteries; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Humans; Ischemia; Mice; Mice, Inbred C57BL; Rats; Stroke; Thrombolytic Therapy; Warfarin | 2013 |
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Health Care Costs; Humans; Models, Economic; Quality-Adjusted Life Years; Stroke; Warfarin | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Dabigatran; Embolism; Female; Humans; Incidence; Male; Middle Aged; Postoperative Complications; Premedication; Retrospective Studies; Risk Assessment; Stroke; Tennessee; Treatment Outcome; Warfarin | 2013 |
Dabigatran bleed risk with closed head injuries: are we prepared?
Topics: Accidental Falls; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage, Traumatic; Clinical Protocols; Craniocerebral Trauma; Dabigatran; Female; Humans; Male; Middle Aged; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Warfarin; Young Adult | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Thromboembolism; Warfarin | 2013 |
Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Topics: Academic Medical Centers; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Substitution; Female; Humans; Male; Referral and Consultation; Stroke; United States; Warfarin | 2013 |
Periprocedural dabigatran in atrial fibrillation ablation: a new kid on the block.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Warfarin | 2013 |
Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Echocardiography; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mitral Valve Stenosis; Rheumatic Heart Disease; Thrombosis; Treatment Outcome; Warfarin | 2013 |
Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Computer Simulation; Coronary Occlusion; Cost-Benefit Analysis; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Markov Chains; Models, Statistical; Ontario; Percutaneous Coronary Intervention; Quality-Adjusted Life Years; Risk Factors; Stroke; Warfarin | 2013 |
Placing a value on new technologies.
Topics: Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coronary Occlusion; Dabigatran; Female; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Male; Percutaneous Coronary Intervention; Stroke; Transplantation; Warfarin | 2013 |
Randomised controlled trial: extended-duration dabigatran is non-inferior to warfarin and more effective than placebo for symptomatic VTE.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Extended anticoagulation in venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Extended anticoagulation in venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Extended anticoagulation in venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Extended anticoagulation in venous thromboembolism.
Topics: Benzimidazoles; beta-Alanine; Female; Humans; Male; Venous Thromboembolism; Warfarin | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran and mechanical valves: less effective and more risky than warfarin.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Postoperative Complications; Thrombosis; Warfarin | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
RE-LYing on dabigatran for periprocedural anticoagulation: is it safe?
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Embolism; Intracranial Thrombosis; Male; Warfarin | 2013 |
[New anticoagulants, new emergencies?].
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Warfarin | 2013 |
Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Device Removal; Drug Administration Schedule; Electric Countershock; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Prosthesis Implantation; Reoperation; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Warfarin | 2013 |
Just because you can, does that mean you should?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Defibrillators, Implantable; Electric Countershock; Female; Humans; Male; Warfarin | 2013 |
Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Thromboembolism; Warfarin | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Anticoagulation-associated upper gastrointestinal haemorrhage.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Medical Audit; Upper Gastrointestinal Tract; Warfarin | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography.
Topics: Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Contrast Media; Dabigatran; Iopamidol; Male; Mice; Radiography, Dual-Energy Scanned Projection; Time Factors; Warfarin | 2013 |
Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stroke; Time Factors; Treatment Outcome; Warfarin | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Female; Humans; Incidence; Intracranial Embolism; Intracranial Thrombosis; Japan; Male; Middle Aged; Premedication; Prospective Studies; Risk Factors; Treatment Outcome; Warfarin | 2013 |
New oral anticoagulants in heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Failure; Humans; Male; Stroke; Warfarin | 2013 |
Response to Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Thromboembolism; Warfarin | 2013 |
Dabigatran - neurosurgical anathema?
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Male; Risk Assessment; Stroke; Thrombosis; Warfarin | 2013 |
Dabigatran and mechanical heart valves--not as easy as we hoped.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2013 |
Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Disease Models, Animal; Hemorrhage; Kidney; Kidney Glomerulus; Male; Rats; Rats, Sprague-Dawley; Warfarin | 2014 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Anticoagulation therapy: Results of RE-ALIGN disappoint.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2013 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2013 |
Acute kidney injury: renal hazards of anticoagulant therapy.
Topics: Acute Kidney Injury; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Rats; Warfarin | 2013 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2013 |
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Warfarin | 2014 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Warfarin | 2013 |
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Topics: Animals; Antithrombins; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Disease Models, Animal; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Rats; Rats, Wistar; Stroke; Tissue Plasminogen Activator; Warfarin | 2014 |
[Prevention and treatment of major bleeding during anticoagulation].
Topics: Administration, Oral; Alcohol Drinking; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Diabetes Mellitus; Drug Therapy, Combination; Factor IX; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Risk Assessment; Risk Factors; Smoking; Vitamin K; Warfarin | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Databases, Factual; Europe; Female; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Stroke; Survival Analysis; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
Dabigatran in the setting of catheter ablation of atrial fibrillation: the road ahead. The authors' reply.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Preoperative Care; Thromboembolism; Warfarin | 2014 |
ACP Journal Club. Dabigatran increased bleeding and stroke compared with warfarin after mechanical heart valve implantation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2013 |
Direct oral anticoagulants for acute venous thromboembolism: closing the circle?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Dabigatran use in mechanical heart valve patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Warfarin | 2014 |
Dabigatran versus warfarin in patients with mechanical heart valves: comment.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Dabigatran versus warfarin in patients with mechanical heart valves: reply.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Dabigatran in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Novel anticoagulants in patients with mechanical heart valves.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Warfarin | 2014 |
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Brain; Brain Injuries; Cerebral Hemorrhage; Dabigatran; Hemorrhage; Mice; Mice, Inbred C57BL; Warfarin | 2014 |
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; United States; United States Food and Drug Administration; Warfarin | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
A new class of powerful and informative simultaneous confidence intervals.
Topics: Algorithms; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biostatistics; Confidence Intervals; Dabigatran; Data Interpretation, Statistical; Humans; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
[Dabigatran versus warfarin in patients with mechanical heart valves].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Heart Valve Prosthesis; Humans; Male; Stroke; Thromboembolism; Warfarin | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hospital Mortality; Humans; Intracranial Hemorrhages; Male; Odds Ratio; Retrospective Studies; Warfarin | 2014 |
Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Topics: Acetylcysteine; Animals; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Pressure; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Free Radical Scavengers; Nephrectomy; Pyrroles; Quinazolines; Rats; Receptor, PAR-1; Renal Insufficiency, Chronic; Vitamin K; Warfarin | 2015 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Female; Humans; Insurance Claim Review; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Risk; Stroke; United States; Warfarin | 2014 |
Treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Dabigatran, bleeding, and the regulators.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Drug Monitoring; Europe; Hemorrhage; Humans; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Warfarin | 2014 |
Haemostasis. Part 2: Medications that affect haemostasis.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Hematologic Agents; Hemostasis, Surgical; Heparin; Humans; International Normalized Ratio; Oral Hemorrhage; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk Assessment; Warfarin | 2014 |
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Substitution; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; International Normalized Ratio; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Stroke; United States; United States Department of Veterans Affairs; Warfarin | 2014 |
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic Agents; Humans; Male; Morpholines; Patient Education as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
ACP Journal Club. In atrial fibrillation, dabigatran had similar efficacy to warfarin but caused less bleeding in higher GFR.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Letter by Seitz and Beurtheret regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing risk analysis from the randomized evaluation of long-term anticoagulant therapy study".
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Warfarin | 2014 |
Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study".
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Warfarin | 2014 |
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Early Detection of Cancer; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Denmark; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Registries; Secondary Prevention; Stroke; Treatment Outcome; Warfarin | 2014 |
Letter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Venous Thromboembolism; Warfarin | 2014 |
Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Surgical Procedures; Comparative Effectiveness Research; Computer Simulation; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Drug Costs; Equipment Design; Female; Health Care Costs; Humans; Male; Markov Chains; Models, Economic; Models, Statistical; Probability; Quality-Adjusted Life Years; Stroke; Treatment Outcome; Uncertainty; Warfarin | 2014 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Additional events in the RE-LY trial.
Topics: Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Stroke; Warfarin | 2014 |
Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Case-Control Studies; Cerebral Hemorrhage; Dabigatran; Humans; Thromboplastin; Warfarin | 2015 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
Myocardial ischemic events in 'real world' patients treated with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Myocardial Ischemia; Warfarin | 2014 |
The reply.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Male; Myocardial Ischemia; Warfarin | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Dose-Response Relationship, Drug; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Kidney Diseases; Medicare; Proportional Hazards Models; Retrospective Studies; Risk; Socioeconomic Factors; Stroke; Treatment Outcome; United States; Warfarin | 2015 |
The importance of postapproval data for dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Risk of bleeding with dabigatran in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Incidence; Male; Medicare; Middle Aged; Retrospective Studies; Risk; United States; Warfarin | 2015 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Stroke; Warfarin | 2015 |
Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; China; Cohort Studies; Dabigatran; Female; Humans; International Normalized Ratio; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Stroke; Time Factors; Warfarin | 2015 |
Letter by Chin et al regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analy
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin | 2014 |
Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysi
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Kidney; Male; Warfarin | 2014 |
Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Heparin; Humans; Lower Extremity; Male; Middle Aged; Severity of Illness Index; Tomography, Spiral Computed; Treatment Outcome; Ultrasonography, Doppler, Duplex; Venous Thromboembolism; Warfarin | 2014 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
[Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Warfarin | 2014 |
Case images: warfarin-induced skin necrosis: a 'novel' solution to an old problem.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Diagnosis, Differential; Humans; Ischemic Attack, Transient; Male; Middle Aged; Necrosis; Skin; Skin Diseases; Thrombosis; Warfarin | 2014 |
[Dabigatran and risk of bleeding].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Letter by Feng et al regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Stroke; Warfarin | 2015 |
Response to letter regarding article, "Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control".
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Intracranial Hemorrhages; Male; Platelet Aggregation Inhibitors; Stroke; Warfarin | 2015 |
The management of dental patients taking new generation oral anticoagulants.
Topics: Anesthetics, Local; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dental Care for Chronically Ill; Drug Interactions; Factor Xa Inhibitors; Hemostatic Techniques; Humans; Morpholines; Oral Surgical Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Patterns of oral anticoagulants use in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Drug Substitution; Drug Utilization Review; Female; Hospitals, University; Humans; Male; Practice Patterns, Physicians'; Quebec; Retrospective Studies; Stroke; Time Factors; Treatment Outcome; Warfarin | 2015 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Humans; Ischemic Attack, Transient; Male; Registries; Stroke; Warfarin | 2015 |
Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.
Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Bleeding Time; Blood Coagulation; Brain; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Hematoma; Mice; Thrombin Time; Warfarin | 2015 |
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Medicaid; Middle Aged; Morpholines; Patient Selection; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Observational Studies as Topic; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Safety of new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
Anticoagulation therapy: Bleeding no worse with novel agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Treatment Outcome; Warfarin | 2015 |
Effective antidotes for new anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
Meta-analysis should not be subject to selectivity and imbalance.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Bleeding in Patients of African Ancestry Using Dabigatran: A Potential Effect of Creatine Kinase.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Hemorrhage; Humans; Male; Warfarin | 2015 |
Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Thiophenes; Warfarin | 2015 |
Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Pulmonary Embolism; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thrombosis; Warfarin | 2015 |
Letter by Lavine Regarding Article, "Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation".
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Medicare; Warfarin | 2015 |
Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2015 |
Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyridones; Rivaroxaban; Stroke; Warfarin | 2016 |
Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin | 2017 |
Anticoagulation therapy: Uninterrupted dabigatran during ablation for AF.
Topics: Anticoagulants; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Warfarin | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic Fractures; Stroke; Warfarin | 2017 |
Osteoporotic Fractures Associated With Dabigatran vs Warfarin-Reply.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Osteoporotic Fractures; Stroke; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Treatment Outcome; Warfarin | 2017 |
Switching off the jitters: Dabigatran as a candidate approach to halt atrial fibrillation?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; beta-Alanine; Dabigatran; Humans; Stroke; Warfarin | 2018 |
Cost-Utility Analysis of Dabigatran and Warfarin for Stroke Prevention Among Patients With Nonvalvular Atrial Fibrillation in India.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Stroke; Warfarin | 2022 |